Carterra is focused on generating large-scale, information-rich binding data using AI, automation, and smarter workflows.
Published
Signal category
Products & Services
Quote
“At #Carterra, we’re focused on helping scientists generate large-scale, information-rich binding data. Combining that type of experimental data with AI, automation, and smarter workflows could open up some very exciting possibilities for the drug discovery community.”
— Gerardo Gutierrez|Carterra team
Company
Carterra
High-throughput SPR technology for antibody and drug discovery enabling fast candidate selection
- Industry
- Biotechnology
- Location
- Salt Lake City, US
- Company size
- 86 employees
Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterra’s flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery and small molecule analysis. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. For additional information, please visit www.carterra-bio.com
Founded 2005